http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101442279-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C217-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C233-43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-227 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C217-60 |
| filingDate | 2007-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101442279-B1 |
| titleOfInvention | derivatives of 4- (2-amino-1-hydroxyethyl) phenol as agonists of the? 2 adrenergic receptor |
| abstract | The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:n n n n n n n n Wherein R 1 is a group selected from -CH 2 OH and -NH (CO) H; R 2 is a hydrogen atom; Or R 1 together with R 2 forms an -NH-C (O) -CH═CH- group, wherein said nitrogen atom is bonded to a carbon atom in the phenyl ring bearing R 1 , said carbon atom being substituted by R 2 Bonded to the carbon atom in the phenyl ring; R 3a and R 3b is independently selected from the group consisting of a hydrogen atom and a C 1-4 alkyl group; X and Y are independently selected from the group consisting of a direct bond and an oxygen atom; n, m and q each independently have a value selected from 0, 1, 2 and 3; p has a value selected from 1, 2 and 3; R 4 and R 5 are independently a hydrogen atom, a halogen atom, C 1-4 alkyl, C 1-4 alkoxy, -CONH 2 , -NHCONH 2 , -SR 7 , -SOR 7 , -SO 2 R 7 , -SO 2 NHR < 8 > and the following groups (a) and (b)n n n n n n n n It is selected from, where, R 7 is selected from C 1-4 alkyl and C 3-8 cycloalkyl, R 8 is selected from hydrogen atoms and C 1-4 alkyl; R 6 is selected from the group consisting of a hydrogen atom, a halogen atom, C 1-4 alkyl and C 1-4 alkoxy.n n n β2 adrenergic receptors, agonists, lung diseases |
| priorityDate | 2006-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 537.